title: A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris.
abstract: We report results of a randomized, vehicle-controlled, bilateral comparison pilot study of bexarotene gel 1% with narrowband UVB (NBUVB) phototherapy for moderate to severe psoriasis. In all, 9 patients applied drug or vehicle gel to comparable target lesions up to twice daily for 10 weeks. NBUVB was initiated 2 weeks after topical therapy began. Limitations include small sample size and interim analysis. Based on analysis of target lesion scores, bexarotene gel 1%/NBUVB was significantly more effective than placebo/NBUVB.
authors.affiliation: Psoriasis Center of Excellence, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901-0019, USA. maglioma@umdnj.edu
authors.forename: Melissa Amy
authors.initials: MA
authors.lastname: Magliocco
authors.forename: Komal
authors.initials: K
authors.lastname: Pandya
authors.forename: Viktor
authors.initials: V
authors.lastname: Dombrovskiy
authors.forename: Linda
authors.initials: L
authors.lastname: Christiansen
authors.forename: Yuk
authors.initials: Y
authors.lastname: Wong
authors.forename: Alice Bendix
authors.initials: AB
authors.lastname: Gottlieb
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000077610:Bexarotene; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D012176:Retinoids / Q000008:administration & dosage / Q000009:adverse effects / Q000138:chemical synthesis / Q000627:therapeutic use; D012720:Severity of Illness Index; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014467:Ultraviolet Therapy
chemical_list: D005782:Gels; D012176:Retinoids; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene